R-roscovitine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
024620042018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Bacterial pneumonia remains associated with high morbidity and mortality. The gram-positive pathogen Streptococcus pneumoniae is… (More)
Is this relevant?
2010
2010
AIM Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
Eosinophils are major players in inflammatory allergic diseases such as asthma, hay fever and eczema. Here we show that the… (More)
Is this relevant?
2008
2008
Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is currently in phase II clinical trials as an… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
The cyclin-dependent kinase (CDK) inhibitor seliciclib (R-roscovitine, CYC202) shows promising antitumor activity in preclinical… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Cyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2005
2005
R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with… (More)
Is this relevant?
2005
2005
BACKGROUND Cyclin-dependent kinase (CDK) inhibition is a new therapeutic approach to proliferative glomerulonephritides. CDK2 is… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their activity by inhibition of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?